Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of SMA patients previously treated with OAV101
NL-OMON59254Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2024
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of onasemnogene abeparvovec in spinal muscular atrophy (SMA) (2 arms), sponsored by Novartis. Primary endpoints: Treatment-emergent serious adverse events and Treatment-emergent adverse events of special interest. Started Sep 2024; status: active, not recruiting.
02
Drugs
onasemnogene abeparvovec
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON59254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59254.